<\/p>\n
Warf<\/strong> is 1 \/ 2 \/ 5 mg warfarin tablets from a WHO-GMP certified manufacturer — an oral vitamin K antagonist (VKA) anticoagulant. Warfarin was first synthesised from dicoumarol in the 1940s and approved as a human drug in 1954; despite the rise of DOACs it remains first-line for mechanical heart valves, moderate-to-severe mitral stenosis, and antiphospholipid syndrome. Mechanism: blocks vitamin K epoxide reductase (VKORC1), depleting the active forms of clotting factors II, VII, IX, X plus proteins C and S. Onset is delayed 3-5 days because circulating factors must decay. Dose is highly individualised and INR-driven — target INR 2.0-3.0 in most indications, 2.5-3.5 for mechanical mitral or older aortic prostheses. Daily intake of vitamin K (greens) should be consistent rather than avoided. Major bleeding rate ~1-3%\/year on therapeutic warfarin. Reversal: oral or IV vitamin K plus 4-factor prothrombin complex concentrate for major bleeding. Specialist or family-physician supervision is standard.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n V\u00e5re generiske legemidler kommer fra WHO-GMP-sertifiserte produsenter og sendes over hele verden i diskret, n\u00f8ytral emballasje \u2014 ingen legemiddelnavn p\u00e5 utsiden av pakken. Kortbetalinger h\u00e5ndteres av en regulert betalingsbehandler (kontoutskrifter viser en regulert kortbetalingsprosessor \u2014 aldri \u201cMedsBase\u201d eller noe legemiddelnavn). Krypto og SEPA bankoverf\u00f8rsel godtas ogs\u00e5. Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy.<\/p>\n Warf is 1 \/ 2 \/ 5 mg warfarin sodium tablets from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Warfarin is the most widely used oral anticoagulant in the world. Despite the introduction of direct oral anticoagulants (DOACs), warfarin remains the first-line choice in mechanical heart valves, rheumatic mitral stenosis, antiphospholipid syndrome, and selected high-risk patients where DOAC evidence is weak.<\/p>\n Warfarin hemmer vitamin K-epoksidreduktase (VKORC1) i hepatocytter, og blokkerer resirkuleringen av vitamin K. Dette reduserer de aktive \u03b3-karboksylerte formene av faktor II, VII, IX og X samt de naturlige antikoagulantia protein C og S. Antikoagulerende effekt forsinkes med 3-5 dager ettersom eksisterende sirkulerende faktorer kataboliseres \u2014 bridging med parenteral heparin eller LMWH er n\u00f8dvendig n\u00e5r rask antikoagulering kreves.<\/p>\n Warfarindosen er sv\u00e6rt individuell og titreres etter den internasjonale normaliserte ratioen (INR). Typisk vedlikeholdsdose er 2\u201310 mg daglig, men varierer fra 15 mg.<\/p>\nHvorfor bestille fra MedsBase<\/h3>\n
What Is Warf?<\/h2>\n
Hvordan Warfarin Virker<\/h2>\n
Godkjente Bruksomr\u00e5der<\/h2>\n
\n
Dosering og INR-m\u00e5l<\/h2>\n